Theriva Biologics reports Q3 EPS ($6.81) vs. ($4.85) last year

“We are very pleased to have completed enrollment in VIRAGE, our Phase 2b trial in metastatic pancreatic ductal adenocarcinoma during the third quarter. Considering the tremendous need for new therapies to treat pancreatic cancer, we have initiated discussions with regulatory agencies to explore the potential expansion of the VIRAGE Phase 2b study into a registrational Phase 3 trial early next year, taking advantage of both Orphan Drug and Fast Track designations. The novel mechanism of action of VCN-01 provides a unique opportunity to expand the treatment landscape in hard-to treat-cancers such as PDAC and retinoblastoma and deliver new interventions that may significantly improve outcomes for patients, ” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics (TOVX). “With funding from the Spanish Government and a small capital raise, we are in a position to advance our proprietary suspension cell line towards larger scale manufacturing of VCN-01 for Phase 3 and commercial use.”